Advertisement

Topics

Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval

02:10 EST 23 Nov 2018 | FinanzNachrichten

BASEL (dpa-AFX) - Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvove...

Original Article: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval

NEXT ARTICLE

More From BioPortfolio on "Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU Approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...